DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Phase 1

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Sacituzumab Govitecan-hziy (SG)

First Posted Date: 2025-04-15

Last Posted Date: 2025-05-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 100

Registration Number: NCT06926920

Locations: 🇺🇸
Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles, California, United States

Study of GS-0151 in Participants With Rheumatoid Arthritis

Phase 1

Not yet recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: GS-0151
Drug: Placebo

First Posted Date: 2025-03-30

Last Posted Date: 2025-03-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 75

Registration Number: NCT06902519

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions: Drug: Sacituzumab Govitecan (SG)
Drug: Topotecan
Drug: Amrubicin (Japan only)

First Posted Date: 2025-01-30

Last Posted Date: 2025-05-07

Lead Sponsor: Gilead Sciences

Target Recruit Count: 695

Registration Number: NCT06801834

Locations: 🇦🇺
Cancer Care Wollongong, New South Wales, Australia
🇺🇸
The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
🇺🇸
Hope and Healing Cancer Services, Hinsdale, Illinois, United States

and more 2 locations

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Recruiting

Conditions: RSV Infection

Interventions: Drug: Obeldesivir Placebo
Drug: Obeldesivir

First Posted Date: 2025-01-20

Last Posted Date: 2025-05-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 130

Registration Number: NCT06784973

Locations: 🇯🇵
Uchida child clinic, Fukuoka, Japan
🇯🇵
Shindo Children's Clinic, Fukuoka, Japan
🇯🇵
SEKI Children's CLINIC, Fukuoka, Japan

and more 47 locations

Expanded Access for Bulevirtide

Conditions: Chronic Hepatitis Delta Virus Infection

First Posted Date: 2025-01-17

Last Posted Date: 2025-01-24

Lead Sponsor: Gilead Sciences

Registration Number: NCT06780579

Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children

Phase 2

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: Oral Lenacapavir
Drug: Subcutaneous Lenacapavir
Drug: Optimized Background Regimen (OBR)

First Posted Date: 2024-12-27

Last Posted Date: 2025-05-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 12

Registration Number: NCT06749054

Locations: 🇿🇦
Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa
🇺🇸
Grady Health System, Ponce De Leon Center, Atlanta, Georgia, United States
🇿🇦
FAMCRU, Cape Town, South Africa

and more 4 locations

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma.

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Domvanalimab
Drug: Zimberelimab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2024-12-11

Last Posted Date: 2025-05-13

Lead Sponsor: Gilead Sciences

Target Recruit Count: 100

Registration Number: NCT06727565

Locations: 🇫🇷
CHU de Bordeaux, Pessac, France
🇮🇹
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
🇪🇸
Hospital Universitario Virgen del Rocio, Sevilla, Spain

and more 22 locations

A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in Spain

Recruiting

Conditions: Breast Cancer

First Posted Date: 2024-11-12

Last Posted Date: 2025-04-13

Lead Sponsor: Gilead Sciences

Target Recruit Count: 50

Registration Number: NCT06683482

Locations: 🇪🇸
Salvetti & Llombart Sl, Barcelona, Catalonia, Spain

Study of Obeldesivir as Postexposure Prophylaxis for Marburg Virus Disease

Phase 2

Not yet recruiting

Conditions: Postexposure Prophylaxis Marburg Virus Disease

Interventions: Drug: obeldesivir

First Posted Date: 2024-11-12

Last Posted Date: 2025-05-06

Lead Sponsor: Gilead Sciences

Target Recruit Count: 400

Registration Number: NCT06682234

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Phase 3

Recruiting

Conditions: HIV-1-infection

Interventions: Drug: ISL/LEN
Drug: B/F/TAF
Drug: PTM B/F/TAF
Drug: PTM ISL/LEN

First Posted Date: 2024-10-08

Last Posted Date: 2025-04-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 600

Registration Number: NCT06630286

Locations: 🇩🇪
EPIMED GmbHGesellschaft fur klinische und epidemiologische Forschung in Berlin, Berlin, Germany
🇩🇪
University Hospital Bonn, Medizinische und Poliklink I, Immunologische Studienambulanz, Bonn, Germany
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 100 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy